TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36151278

Group type: COMPARATOR
Intervention: 1,450 ppm fluoride toothpaste
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5,000 ppm fluoride toothpaste
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1,450 ppm fluoride toothpaste + 0.2% sodium fluoride mouth rinse
Number of subjects: 0
Study: 32106527

Group type: EXPERIMENTAL
Intervention: Liquid PEA (167.5 mg Levagen+ with 832.5 mg maltodextrin)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Matched placebo (1 g maltodextrin)
Number of subjects: 28
Study: 33140673

Group type: EXPERIMENTAL
Intervention: High CPA risk parents
Number of subjects: 165

Group type: COMPARATOR
Intervention: Low CPA risk parents in high loss condition
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Higher levels of child provocation
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Aggressive motives
Number of subjects: 165
Study: 34775865

Group type: EXPERIMENTAL
Intervention: 1% glucose isotonic electrolyte solution
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 100
Study: 32915904

Group type: EXPERIMENTAL
Intervention: Automated vessel density detection from ultra-widefield fluorescein angiography (UWFFA) images
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Automated vessel density detection from UWFFA images
Number of subjects: 42
Study: 35165795

Group type: EXPERIMENTAL
Intervention: HIV-positive women
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: HIV-negative women
Number of subjects: 700
Study: 34398237

Group type: EXPERIMENTAL
Intervention: Rosuvastatin therapy for 48 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35475874

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32624569

Group type: EXPERIMENTAL
Intervention: 150mg L-DOPA
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 3 mg haloperidol
Number of subjects: 27

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study: 35173278

Group type: EXPERIMENTAL
Intervention: Combined training (CT)
Number of subjects: 34
Study: 32701397

Group type: EXPERIMENTAL
Intervention: MUST-Plus (machine learning classifier)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MUST (Malnutrition Universal Screening Tool)
Number of subjects: 0
Study: 32592439

Group type: EXPERIMENTAL
Intervention: 3 × 3 hour group intervention aiming to prevent symptoms of stress‐related ill health by increasing engagement in proactive behaviors.
Number of subjects: 239

Group type: COMPARATOR
Intervention: Control intervention (active control condition).
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Greater adherence to the intervention.
Number of subjects: 239
Study: 36404406

Group type: EXPERIMENTAL
Intervention: HeartMate 3 (HM3)
Number of subjects: 918

Group type: COMPARATOR
Intervention: HeartMate II (HMII)
Number of subjects: 918
Study: 35918638

Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB) combined with general anesthesia (group E)
Number of subjects: 60
Study: 33475734

Group type: EXPERIMENTAL
Intervention: Etrasimod 2 mg
Number of subjects: 118
Study: 32344455

Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg once daily for one week
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 33221594

Group type: EXPERIMENTAL
Intervention: Three stone fire
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cookstoves (various)
Number of subjects: 48
Study: 35016094

Group type: EXPERIMENTAL
Intervention: Vie Scope® laryngoscope
Number of subjects: 90

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 90
Study: 32962936

Group type: EXPERIMENTAL
Intervention: Sugammadex, 4 mg/kg
Number of subjects: 60
Study: 32877651

Group type: EXPERIMENTAL
Intervention: Trimetazidine 35 mg modified-release twice daily
Number of subjects: 6007

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6007
Study: 35779276

Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 1635

Group type: COMPARATOR
Intervention: Health Education (HE) intervention
Number of subjects: 1635
Study: 33761688

Group type: EXPERIMENTAL
Intervention: Qiming granule combined with laser treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple laser treatment
Number of subjects: 0
Study: 35395778

Group type: EXPERIMENTAL
Intervention: Model-based social media intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 0
Study: 33596251

Group type: EXPERIMENTAL
Intervention: Health benefits framing
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Cost benefits framing
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Social norms framing
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Overall swaps offered
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Overall energy change per product
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Overall energy change per shopping basket
Number of subjects: 900
Study: 32551819

Group type: EXPERIMENTAL
Intervention: Dialectical behaviour therapy
Number of subjects: 162

Group type: COMPARATOR
Intervention: Conversational model
Number of subjects: 162
Study: 35259535

Group type: EXPERIMENTAL
Intervention: Dupilumab 200/300 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32909336

Group type: EXPERIMENTAL
Intervention: Respirator liner made of polyurethane foam designed to redistribute pressure across the face.
Number of subjects: 1161
Study: 32928196

Group type: EXPERIMENTAL
Intervention: Adaptive tutorials for head CT
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Adaptive tutorials for chest CT
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Adaptive tutorials
Number of subjects: 91

Group type: COMPARATOR
Intervention: Web-based resources
Number of subjects: 91
Study: 34153006

Group type: EXPERIMENTAL
Intervention: Intrathecal 2‐chloroprocaine 3% 50 mg with fentanyl 15 µg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine 0.75% 9 mg with fentanyl 15 µg
Number of subjects: 43
Study: 34489189

Group type: EXPERIMENTAL
Intervention: Health coaching (PuSHCon)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 87
Study: 33975569

Group type: EXPERIMENTAL
Intervention: Healthy School Start Plus (HSSP) programme, which includes classroom activities and home assignments for children.
Number of subjects: 36
Study: 34185138

Group type: EXPERIMENTAL
Intervention: Optimized dose regimen based on BMI
Number of subjects: 78
Study: 32299763

Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA, 20 min, 2 sessions/day for five weekdays)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 60
Study: 34217851

Group type: EXPERIMENTAL
Intervention: Long-interval dinoprostone (3 mg vaginally 12 hours before OH)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Short-interval dinoprostone (3 mg vaginally 3 hours before OH)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Long-interval dinoprostone
Number of subjects: 180

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 180
Study: 34655175

Group type: EXPERIMENTAL
Intervention: FL followed by PTX (FL/PTX)
Number of subjects: 94

Group type: COMPARATOR
Intervention: FL followed by best supportive care (FL/BSC)
Number of subjects: 94

Group type: COMPARATOR
Intervention: FLTAX (5‐fluorouracil/leucovorin and paclitaxel)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: FLTAX
Number of subjects: 94
Study: 33465041

Group type: EXPERIMENTAL
Intervention: Skin Failure Clinical Indicator Scale (SFCIS)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Serum albumin level < 3.5 mg/dL
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Impaired blood flow
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Presence of sepsis/multiorgan dysfunction syndrome
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Vasopressor/inotrope use
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 52
Study: 33611722

Group type: EXPERIMENTAL
Intervention: Head CTs
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Shunt series x-rays
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MRIs
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Radiation exposure
Number of subjects: 100
Study: 35050548

Group type: EXPERIMENTAL
Intervention: Valsartan oral solution 160 mg
Number of subjects: 82

Group type: COMPARATOR
Intervention: Valsartan suspension formulation
Number of subjects: 82
Study: 34193267

Group type: EXPERIMENTAL
Intervention: FIFA 11 + shoulder programme (11 + S) performed as warm up protocol, three times per week
Number of subjects: 32

Group type: COMPARATOR
Intervention: Routine warm up protocol
Number of subjects: 32
Study: 32713290

Group type: EXPERIMENTAL
Intervention: PRECIOUS only (app + biofeedback + follow‐ups)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: PRECIOUS + MI (app + biofeedback + motivational interviewing follow‐ups)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (TAU + biofeedback + follow‐ups)
Number of subjects: 31
Study: 33529502

Group type: EXPERIMENTAL
Intervention: Er:YAG laser (G1; n = 12)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser (G2; n = 13)
Number of subjects: 25
Study: 36269670

Group type: EXPERIMENTAL
Intervention: Positive self-disclosure posts
Number of subjects: 382

Group type: COMPARATOR
Intervention: Negative self-disclosure posts
Number of subjects: 382
Study: 33357057

Group type: EXPERIMENTAL
Intervention: Screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EaveTubes
Number of subjects: 0
Study: 34753859

Group type: EXPERIMENTAL
Intervention: Low carbohydrate-to-protein ratio intervention
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: High carbohydrate-to-protein ratio intervention
Number of subjects: 61

Group type: COMPARATOR
Intervention: Usual dietary habits
Number of subjects: 61
Study: 34903585

Group type: EXPERIMENTAL
Intervention: Oral morphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transmucosal diamorphine
Number of subjects: 0
Study: 35984425

Group type: EXPERIMENTAL
Intervention: Liraglutide (GLP-1RA)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Empagliflozin (SGLT2i)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Sitagliptin (DPP-4 inhibitor)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Dietary interventions
Number of subjects: 148
Study: 34114882

Group type: EXPERIMENTAL
Intervention: Genetic correlation analyses, look-up analyses, and Mendelian randomization (MR) studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mendelian randomization (MR) studies
Number of subjects: 0
Study: 32971991

Group type: EXPERIMENTAL
Intervention: Kiwifruit (2 SunGold™ kiwifruit/day)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Vitamin C (250 mg tablet/day)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo (1 tablet/day)
Number of subjects: 167
Study: 34260297

Group type: EXPERIMENTAL
Intervention: NACRT (Neoadjuvant chemoradiotherapy) combined with postoperative adjuvant XELOX chemotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: ACT (Postoperative adjuvant chemotherapy with XELOX)
Number of subjects: 60
Study: 32144924

Group type: EXPERIMENTAL
Intervention: Single acupoint Zusanli (ST36)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Multi-acupoints Zusanli (ST36), Shangjuxu (ST37) and Neiguan (PC6)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (routine basic treatments)
Number of subjects: 70
Study: 35998283

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 35211483

Group type: EXPERIMENTAL
Intervention: TeleClinical Care (TCC)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control
Number of subjects: 164
Study: 35133871

Group type: EXPERIMENTAL
Intervention: Copanlisib (60 mg intravenous) once weekly on days 1, 8, and 15 in 28-day cycles until progression or toxicity
Number of subjects: 25
Study: 32757247

Group type: EXPERIMENTAL
Intervention: ITR-containing product for three weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no ITR treatment)
Number of subjects: 30
Study: 36226865

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32745227

Group type: EXPERIMENTAL
Intervention: Autogenous bone graft (ABG)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Demineralized bone matrix (DBM)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: No graft (NG)
Number of subjects: 153
Study: 616588608

Group type: EXPERIMENTAL
Intervention: Text message reminders (texting group)
Number of subjects: 6989

Group type: COMPARATOR
Intervention: Traditional phone call reminder (nontexting group)
Number of subjects: 6989
Study: 35644335

Group type: EXPERIMENTAL
Intervention: Retrieval of IVC filters
Number of subjects: 100
Study: 34090765

Group type: EXPERIMENTAL
Intervention: 20% urea cream
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 5% urea cream
Number of subjects: 60
Study: 32026432

Group type: EXPERIMENTAL
Intervention: Maintenance therapy with rituximab
Number of subjects: 66

Group type: COMPARATOR
Intervention: No maintenance therapy (observation with serial MRI scans)
Number of subjects: 66
Study: 35397950

Group type: EXPERIMENTAL
Intervention: More intensive blood pressure control strategy
Number of subjects: 60870
Study: 33882601

Group type: EXPERIMENTAL
Intervention: TCC‐Cardiac app
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: TCC‐COVID app
Number of subjects: 164
Study: 32991492

Group type: EXPERIMENTAL
Intervention: Maternal use of beta-blockers during the first trimester of pregnancy
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Maternal use of progestogens during the first trimester of pregnancy
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Young maternal age (less than 25 years)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Primiparity
Number of subjects: 106
Study: 34487087

Group type: EXPERIMENTAL
Intervention: Obese children
Number of subjects: 91
Study: 35647823

Group type: EXPERIMENTAL
Intervention: Dezocine combined with dexmedetomidine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (Dezocine only)
Number of subjects: 80
Study: 33308038

Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis MN-Gup yogurt
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo yogurt
Number of subjects: 0
Study: 32389105

Group type: EXPERIMENTAL
Intervention: Liberal blood glucose control (target 10.0-14.0 mmol/L)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Usual care (target 6.0-10.0 mmol/L)
Number of subjects: 450
Study: 35085524

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass graft surgery
Number of subjects: 768

Group type: COMPARATOR
Intervention: On-pump coronary artery bypass graft surgery
Number of subjects: 768
Study: 33731111

Group type: EXPERIMENTAL
Intervention: Attractive Targeted Sugar Baits (ATSBs)
Number of subjects: 0
Study: 35173379

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) training for 5 weeks, twice a week, 30 min sessions
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no vibration during training)
Number of subjects: 96
Study: 33689853

Group type: EXPERIMENTAL
Intervention: Deep Learning-Based Computed Tomography Perfusion Mapping (DL-CTPM)
Number of subjects: 146
Study: 35509000

Group type: EXPERIMENTAL
Intervention: Stress condition (Trier Social Stress Test for Groups)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control condition (Trier Social Stress Test for Groups)
Number of subjects: 70
Study: 34563227

Group type: EXPERIMENTAL
Intervention: Clinician-directed nudges
Number of subjects: 5500

Group type: EXPERIMENTAL
Intervention: Patient-directed nudges
Number of subjects: 5500

Group type: EXPERIMENTAL
Intervention: Combination of clinician and patient-directed nudges
Number of subjects: 5500

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 5500
Study: 34953526

Group type: EXPERIMENTAL
Intervention: Ad5-nCoV vaccine (0.5 mL dose of 5 × 10^10 viral particle/mL)
Number of subjects: 36717

Group type: COMPARATOR
Intervention: Placebo (0.5 mL)
Number of subjects: 36717

Group type: EXPERIMENTAL
Intervention: Ad5-nCoV vaccine
Number of subjects: 36717

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36717
Study: 36383249

Group type: EXPERIMENTAL
Intervention: Caffeine containing multi-ingredient pre-workout supplement (SUPP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Color and flavor matched placebo (PL)
Number of subjects: 10
Study: 35338753

Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia (AIH) - 30 minutes of alternating 1-minute hypoxia (FiO2 ≈ 0.09) and 1-minute normoxia
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham intervention (normoxia, FiO2 ≈ 0.21)
Number of subjects: 14
Study: 34036721

Group type: EXPERIMENTAL
Intervention: Tumour-treating fields (TTFields)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care therapies (radiotherapy and temozolomide chemotherapy)
Number of subjects: 0
Study: 34339267

Group type: COMPARATOR
Intervention: SPR206 (10 mg to 400 mg single doses; 25 mg to 150 mg every 8 hours for 7 days; 100 mg every 8 hours for 14 days)
Number of subjects: 94

Group type: COMPARATOR
Intervention: SPR206 (100 mg every 8 hours for 14 days)
Number of subjects: 94

Group type: COMPARATOR
Intervention: SPR206 (various doses)
Number of subjects: 94
Study: 34444802

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (6-month program including six group seminars and eight telephone consultations)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 404

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 404
Study: 36202908

Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium (PPS) monotherapy for 16 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 26
Study: 33767111

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Attention Control (AC)
Number of subjects: 127
Study: 35381230

Group type: EXPERIMENTAL
Intervention: Disposable gastroscopes
Number of subjects: 110

Group type: COMPARATOR
Intervention: Reusable gastroscopes
Number of subjects: 110
Study: 34706189

Group type: EXPERIMENTAL
Intervention: Sotrovimab (500 mg single infusion)
Number of subjects: 583

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 583

Group type: EXPERIMENTAL
Intervention: Sotrovimab
Number of subjects: 583
Study: 33382746

Group type: EXPERIMENTAL
Intervention: Da Qing Diabetes Prevention program (DQDP)
Number of subjects: 0
Study: 36289063

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg once daily
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 35133556

Group type: EXPERIMENTAL
Intervention: PCIT-ED treatment (n=94)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Waitlist control (n=91)
Number of subjects: 185
Study: 32144803

Group type: EXPERIMENTAL
Intervention: Immediate non-occlusal implant loading
Number of subjects: 60

Group type: COMPARATOR
Intervention: Early non-occlusal implant loading
Number of subjects: 60
Study: 34779226

Group type: EXPERIMENTAL
Intervention: Patients fulfilling MR CLEAN criteria
Number of subjects: 2611

Group type: COMPARATOR
Intervention: Patients not fulfilling MR CLEAN criteria
Number of subjects: 2611
Study: 33258358

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicines (CHMs)
Number of subjects: 510

Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 510
Study: 34645442

Group type: EXPERIMENTAL
Intervention: In-person recruitment
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Recruitment at healthcare providers' offices
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Recruitment via mail
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Additional study information
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Frequent calls
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Placement of flyers at clinics
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Financial incentives
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Formal events
Number of subjects: 25
Study: 33047689

Group type: EXPERIMENTAL
Intervention: ARFI (Acoustic Radiation Force‐Based Elasticity Imaging)
Number of subjects: 45
Study: 34227411

Group type: EXPERIMENTAL
Intervention: Multimedia website information
Number of subjects: 109

Group type: COMPARATOR
Intervention: Standard printed information
Number of subjects: 109
Study: 32936420

Group type: EXPERIMENTAL
Intervention: SMART-CT index (developed using 7 statistically significant items from CT scans)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: SMART-CT index
Number of subjects: 123
Study: 35016914

Group type: EXPERIMENTAL
Intervention: 10 mg escitalopram
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 34743631

Group type: EXPERIMENTAL
Intervention: 3D phantom training (Group P)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Audiovisual lecture only (Group L)
Number of subjects: 0
Study: 37086245

Group type: EXPERIMENTAL
Intervention: Istaroxime (0.5 mg/kg/min)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Istaroxime (1.0 mg/kg/min)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control subjects (saline placebo)
Number of subjects: 26
Study: 33235342

Group type: EXPERIMENTAL
Intervention: Chronic medication with anticoagulants or antihypertensives
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Follow-up at V2
Number of subjects: 68
Study: 35033356

Group type: EXPERIMENTAL
Intervention: IO+IA-PRP (intra-osseous, intra-articular PRP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: IA-PRP (intra-articular PRP)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: IO+IA-PRP
Number of subjects: 50

Group type: COMPARATOR
Intervention: IA-PRP
Number of subjects: 50
Study: 33653271

Group type: COMPARATOR
Intervention: Conventional oxygen therapy (COT) - FiO2 of 1.0, 12 L/min
Number of subjects: 150

Group type: COMPARATOR
Intervention: Normal frequency jet ventilation (NFJV) - FiO2 of 1.0, driving pressure of 0.1 MPa, RR 15 bpm
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: High frequency jet ventilation (HFJV) - FiO2 of 1.0, driving pressure of 0.1 MPa, RR 1200 bpm
Number of subjects: 150